Johnson & Johnson Offers $5.5 Billion Settlement to Resolve Decades-Long Baby Powder Lawsuits
New Brunswick, Wednesday, 29 July 2026.
Healthcare giant Johnson & Johnson proposed paying $5.5 billion to resolve roughly 76,000 ovarian cancer lawsuits, seeking to end over a decade of high-profile legal battles.
Johnson & Johnson Proposes $5.5 Billion Settlement
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) has proposed a $5.5 billion settlement agreement to resolve approximately 76,000 pending lawsuits claiming its talc-based baby powder caused ovarian cancer [1][2]. The proposal, disclosed on July 29, 2026, requires approval from 95% of claimants to finalize the agreement and clear a major legal liability that has weighed on the company’s valuation and strategic outlook for years [1][4].
Settlement Overview
This settlement aims to tie up remaining lawsuits that claim the company’s talc products caused ovarian cancer, covering claims consolidated in federal court in New Jersey and related cases in state courts [1][5]. To finalize the agreement, the proposal requires acceptance by legal firms representing 95% of ovarian cancer claims in state and federal courts [3][5].
Financial Structure and Payment Schedule
As part of the settlement proposed this week, Johnson & Johnson will make an initial payment of no more than $3 billion next year [1][6]. It has no additional payments due until 2028, with the final total potentially exceeding $7 billion depending on claimant participation rates [2][6].
Market Reaction
Shares of the New Brunswick, New Jersey-based company rose more than 2% before the market open on Tuesday following the news [1][8]. This market reaction suggests investor relief at the prospect of removing long-standing legal uncertainty from the company’s balance sheet [4][8].
Legal Context and Company Stance
A federal judge recently ordered plaintiffs in the case against Johnson & Johnson to show why the remaining pending talc claims should not be dismissed after their witnesses could not provide a direct link between the company’s product and cancer [1][6]. Despite this legal advantage, the company stated that the resolution allows it to remain focused on its mission to develop medicines and devices that save lives [5][7].
Strategic Implications
Johnson & Johnson previously settled about 95% of filed lawsuits for mesothelioma and all state consumer protection claims prior to this proposal [1][5]. The average payout per claimant can be estimated based on the total settlement value divided by the number of claims 72368.421 [2][3].